View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 2, 2011updated 22 Nov 2021 12:39pm

FDA clears Pacira post-surgical pain management therapy

The US Food and Drug Administration (FDA) has approved Pacira Pharmaceuticals' Exparel (bupivacaine liposome injectable suspension) 1.3% for post-surgical pain management.

The US Food and Drug Administration (FDA) has approved Pacira Pharmaceuticals‘ Exparel (bupivacaine liposome injectable suspension) 1.3% for post-surgical pain management.

Exparel is a multivesicular liposomal combined therapy product including bupivacaine, delivered using DepoFoam technology.

Exparel with DepoFoam delivers bupivacaine for an extended period of time, providing analgesia for up to 72 hours with reduced opioid consumption.

University of California surgery associate professor Sonia Ramamoorthy said that Exparel “has the potential to reduce or delay the use of opioids following inpatient and outpatient surgical procedures”.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena